Published in Genes Immun on October 01, 2009
Early changes in natural killer cell function indicate virologic response to interferon therapy for hepatitis C. Gastroenterology (2011) 2.33
Lambda interferon renders epithelial cells of the respiratory and gastrointestinal tracts resistant to viral infections. J Virol (2010) 2.28
Interferon-lambda: a new addition to an old family. J Interferon Cytokine Res (2010) 2.15
Human type 2 myeloid dendritic cells produce interferon-λ and amplify interferon-α in response to hepatitis C virus infection. Gastroenterology (2012) 1.80
Induction and function of type I and III interferon in response to viral infection. Curr Opin Virol (2011) 1.61
IFN-λs. Curr Opin Immunol (2011) 1.48
IL-28A (IFN-λ2) modulates lung DC function to promote Th1 immune skewing and suppress allergic airway disease. EMBO Mol Med (2011) 1.44
Early changes in interferon signaling define natural killer cell response and refractoriness to interferon-based therapy of hepatitis C patients. Hepatology (2011) 1.32
Interferon lambdas: the next cytokine storm. Gut (2011) 1.25
Antitumor activity of type I and type III interferons in BNL hepatoma model. Cancer Immunol Immunother (2010) 1.19
IL28B in hepatitis C virus infection: translating pharmacogenomics into clinical practice. J Gastroenterol (2010) 1.18
Interferon-λ: Immune Functions at Barrier Surfaces and Beyond. Immunity (2015) 1.16
Evolutionary divergence and functions of the human interleukin (IL) gene family. Hum Genomics (2010) 1.15
NK cells require IL-28R for optimal in vivo activity. Proc Natl Acad Sci U S A (2015) 1.14
Guarding the frontiers: the biology of type III interferons. Nat Immunol (2015) 1.12
Lambda and alpha interferons inhibit hepatitis B virus replication through a common molecular mechanism but with different in vivo activities. Virology (2010) 1.10
Interferon lambda: a new sword in cancer immunotherapy. Clin Dev Immunol (2011) 1.04
Interferon-λ in HCV Infection and Therapy. Viruses (2010) 0.98
Subversion of cytokine networks by virally encoded decoy receptors. Immunol Rev (2012) 0.98
Interferons: Success in anti-viral immunotherapy. Cytokine Growth Factor Rev (2014) 0.98
Age-associated impaired plasmacytoid dendritic cell functions lead to decreased CD4 and CD8 T cell immunity. Age (Dordr) (2010) 0.98
The impact of the interferon-lambda family on the innate and adaptive immune response to viral infections. Emerg Microbes Infect (2014) 0.96
Bovine type III interferon significantly delays and reduces the severity of foot-and-mouth disease in cattle. J Virol (2012) 0.94
Epigenetic reprogramming of the type III interferon response potentiates antiviral activity and suppresses tumor growth. PLoS Biol (2014) 0.93
Interleukin-29 modulates proinflammatory cytokine production in synovial inflammation of rheumatoid arthritis. Arthritis Res Ther (2012) 0.91
Induction of an antiviral state and attenuated coxsackievirus replication in type III interferon-treated primary human pancreatic islets. J Virol (2013) 0.91
Type III IFN receptor expression and functional characterisation in the pteropid bat, Pteropus alecto. PLoS One (2011) 0.87
Genetically associated CD16(+)56(-) natural killer cell interferon (IFN)-αR expression regulates signaling and is implicated in IFN-α-induced hepatitis C virus decline. J Infect Dis (2012) 0.86
Transcriptome analysis reveals a classical interferon signature induced by IFNλ4 in human primary cells. Genes Immun (2015) 0.86
Interferon-λ1 linked to a stabilized dimer of Fab potently enhances both antitumor and antiviral activities in targeted cells. PLoS One (2013) 0.85
Glucocorticosteroids enhance replication of respiratory viruses: effect of adjuvant interferon. Sci Rep (2014) 0.84
Impact of immunogenetic IL28B polymorphism on natural outcome of HCV infection. Biomed Res Int (2014) 0.83
The role of macrophage IL-10/innate IFN interplay during virus-induced asthma. Rev Med Virol (2014) 0.82
IL28B polymorphisms as a pretreatment predictor of response to HCV treatment. Infect Dis Clin North Am (2012) 0.81
The impact of interferon lambda 3 gene polymorphism on natural course and treatment of hepatitis C. Clin Dev Immunol (2012) 0.81
Cellular Antiviral Factors that Target Particle Infectivity of HIV-1. Curr HIV Res (2016) 0.80
Interferon lambda inhibits dengue virus replication in epithelial cells. Virol J (2015) 0.79
Peginterferon Lambda-1a, a New Therapeutic for Hepatitis C Infection, from Bench to Clinic. J Clin Transl Hepatol (2013) 0.79
Interferon at the crossroads of allergy and viral infections. J Leukoc Biol (2015) 0.79
Expression of Ifnlr1 on intestinal epithelial cells is critical to the antiviral effects of IFN-lambda against norovirus and reovirus. J Virol (2017) 0.78
Immune Cell Profiling of IFN-λ Response Shows pDCs Express Highest Level of IFN-λR1 and Are Directly Responsive via the JAK-STAT Pathway. J Interferon Cytokine Res (2016) 0.78
IFN-λ exerts opposing effects on T cell responses depending on the chronicity of the virus infection. J Immunol (2014) 0.77
Hepatic metallothionein expression in chronic hepatitis C virus infection is IFNL3 genotype-dependent. Genes Immun (2014) 0.77
Dendritic cells in hepatitis C virus infection: key players in the IFNL3-genotype response. World J Gastroenterol (2014) 0.77
Recent advances in the anti-HCV mechanisms of interferon. Acta Pharm Sin B (2014) 0.77
Detection of allele specific differences in IFNL3 (IL28B) mRNA expression. BMC Med Genet (2014) 0.77
Effect of human interferon-λ1 recombinant adenovirus on a gastric cancer orthotopic transplantation model. Exp Ther Med (2014) 0.77
Comparison of antiviral activity of lambda-interferons against HIV replication in macrophages. J Interferon Cytokine Res (2014) 0.76
Type III interferons are expressed by Coxsackievirus-infected human primary hepatocytes and regulate hepatocyte permissiveness to infection. Clin Exp Immunol (2014) 0.76
IFNL3/4 genotype is associated with altered immune cell populations in peripheral blood in chronic hepatitis C infection. Genes Immun (2016) 0.75
Identification, Characterization, and Developmental Expression Pattern of Type III Interferon Receptor Gene in the Chinese Goose. Biomed Res Int (2015) 0.75
Respiratory syncytial virus infection induces a subset of types I and III interferons in human dendritic cells. Virology (2017) 0.75
Interferon Lambda: Modulating Immunity in Infectious Diseases. Front Immunol (2017) 0.75
Interleukin-10 receptor-1 expression in monocyte-derived antigen-presenting cell populations: dendritic cells partially escape from IL-10's inhibitory mechanisms. Genes Immun (2014) 0.75
Type III interferon attenuates a vesicular stomatitis virus-based vaccine vector. J Virol (2014) 0.75
Functional characterization of canine interferon-lambda. J Interferon Cytokine Res (2014) 0.75
Type III Interferons in Hepatitis C Virus Infection. Front Immunol (2016) 0.75
IFN-λ3 polymorphism indirectly influences NK cell phenotype and function during acute HCV infection. Immun Inflamm Dis (2016) 0.75
Contribution of Type III Interferons to Antiviral Immunity; Location, Location, Location. J Biol Chem (2017) 0.75
IFNλ Stimulates MxA Production in Human Dermal Fibroblasts via a MAPK-Dependent STAT1-Independent Mechanism. J Invest Dermatol (2015) 0.75
IFN-λ: A New Class of Interferon with Distinct Functions-Implications for Hepatitis C Virus Research. Gastroenterol Res Pract (2015) 0.75
Standardization of human IL-29 (IFN-λ1): establishment of a World Health Organization international reference reagent for IL-29 (IFN-λ1). J Interferon Cytokine Res (2014) 0.75
IFN-λ Inhibits Drug-Resistant HIV Infection of Macrophages. Front Immunol (2017) 0.75
Lambda Interferons: New Cytokines with Old Functions. Pharmaceuticals (Basel) (2010) 0.75
Tick-Borne Viruses and Biological Processes at the Tick-Host-Virus Interface. Front Cell Infect Microbiol (2017) 0.75
Interferon-Lambda: A Potent Regulator of Intestinal Viral Infections. Front Immunol (2017) 0.75
The dynamic changes of interferon lambdas related genes and proteins in JAK/STAT pathway in both acute and chronic HIV-1 infected patients. AIDS Res Ther (2017) 0.75
Peg-Interferon Lambda Treatment Induces Robust Innate and Adaptive Immunity in Chronic Hepatitis B Patients. Front Immunol (2017) 0.75
Monocyte deactivation in septic patients: restoration by IFN-gamma treatment. Nat Med (1997) 5.19
Interleukin-10 therapy--review of a new approach. Pharmacol Rev (2003) 3.51
Sympathetic activation triggers systemic interleukin-10 release in immunodepression induced by brain injury. Nat Med (1998) 2.30
Monocyte deactivation--rationale for a new therapeutic strategy in sepsis. Intensive Care Med (1996) 2.00
Penetration of titanium dioxide microparticles in a sunscreen formulation into the horny layer and the follicular orifice. Skin Pharmacol Appl Skin Physiol (1999) 1.67
Detection of early micrometastases in subcutaneous fat of primary malignant melanoma patients by identification of tyrosinase-mRNA. Eur J Cancer (1996) 1.59
Organization of the monocyte/macrophage system of normal human skin. J Invest Dermatol (1990) 1.58
Impaired antigen presentation by human monocytes during endotoxin tolerance. Blood (2000) 1.58
Analysis of V(H)-D-J(H) gene transcripts in B cells infiltrating the salivary glands and lymph node tissues of patients with Sjögren's syndrome. Arthritis Rheum (1999) 1.56
Molecular mechanisms of interleukin-10-mediated inhibition of NF-kappaB activity: a role for p50. Clin Exp Immunol (2004) 1.56
HLA type-independent method to monitor polyoma BK virus-specific CD4 and CD8 T-cell immunity. Am J Transplant (2006) 1.56
Is there an interaction between interleukin-10 and interleukin-22? Genes Immun (2005) 1.54
Polyclonal expansion of T cells with the TCR V beta type of the tumour cell in lesions of cutaneous T-cell lymphoma: evidence for possible superantigen involvement. Br J Dermatol (2004) 1.53
New onset or exacerbation of psoriatic skin lesions in patients with definite rheumatoid arthritis receiving tumour necrosis factor alpha antagonists. Ann Rheum Dis (2005) 1.47
Demonstration of frequent occurrence of clonal T cells in the peripheral blood but not in the skin of patients with small plaque parapsoriasis. Blood (1999) 1.47
Hypocomplementaemic urticarial vasculitis: successful treatment with cyclophosphamide-dexamethasone pulse therapy. Br J Dermatol (1998) 1.47
Identification of common dermatophytes (Trichophyton, Microsporum, Epidermophyton) using polymerase chain reactions. Br J Dermatol (1998) 1.44
T-cell receptor and immunoglobulin gene rearrangements in cutaneous T-cell-rich pseudolymphomas. J Invest Dermatol (1990) 1.43
A randomised study of topical 5% imiquimod vs. topical 5-fluorouracil vs. cryosurgery in immunocompetent patients with actinic keratoses: a comparison of clinical and histological outcomes including 1-year follow-up. Br J Dermatol (2007) 1.42
IL-10 is a key cytokine in psoriasis. Proof of principle by IL-10 therapy: a new therapeutic approach. J Clin Invest (1998) 1.40
Verrucosis of hands and feet in a patient with combined immune deficiency. J Am Acad Dermatol (1997) 1.39
Inhibition of keratinocyte apoptosis by IL-15: a new parameter in the pathogenesis of psoriasis? J Immunol (2000) 1.29
Prevention of non-melanoma skin cancer in organ transplant patients by regular use of a sunscreen: a 24 months, prospective, case-control study. Br J Dermatol (2009) 1.28
Cutaneous side-effects in patients with rheumatic diseases during application of tumour necrosis factor-alpha antagonists. Br J Dermatol (2007) 1.28
Brain death activates donor organs and is associated with a worse I/R injury after liver transplantation. Am J Transplant (2007) 1.26
Release of doxorubicin in sweat: first step to induce the palmar-plantar erythrodysesthesia syndrome? Ann Oncol (2005) 1.25
A continuous T-cell line from a patient with Sézary syndrome. Arch Dermatol Res (1987) 1.23
Early post-transplant urinary IP-10 expression after kidney transplantation is predictive of short- and long-term graft function. Kidney Int (2006) 1.21
Actinic keratosis is an early in situ squamous cell carcinoma: a proposal for reclassification. Br J Dermatol (2007) 1.21
Sclerotherapy for treatment of hemangiomas. Dermatol Surg (2000) 1.19
Secondary structure as primary determinant of the efficiency of ribosomal binding sites in Escherichia coli. Nucleic Acids Res (1986) 1.18
Protein kinases as small molecule inhibitor targets in inflammation. Curr Med Chem (2007) 1.17
TCR repertoire analysis by next generation sequencing allows complex differential diagnosis of T cell-related pathology. Am J Transplant (2013) 1.16
Candida africana sp. nov., a new human pathogen or a variant of Candida albicans? Mycoses (2001) 1.14
Hair follicles--an efficient storage and penetration pathway for topically applied substances. Summary of recent results obtained at the Center of Experimental and Applied Cutaneous Physiology, Charité -Universitätsmedizin Berlin, Germany. Skin Pharmacol Physiol (2008) 1.12
Resistance of melanoma cells to TRAIL does not result from upregulation of antiapoptotic proteins by NF-kappaB but is related to downregulation of initiator caspases and DR4. Oncogene (2006) 1.12
Sunscreen application at the beach. J Cosmet Dermatol (2004) 1.12
Modulation of human T cell responses and macrophage functions by onchocystatin, a secreted protein of the filarial nematode Onchocerca volvulus. J Immunol (2001) 1.12
Oligonucleotide typing reveals association of type I psoriasis with the HLA-DRB1*0701/2, -DQA1*0201, -DQB1*0303 extended haplotype. J Invest Dermatol (1993) 1.12
CLinical experience acquired with the efalizumab (Raptiva) (CLEAR) trial in patients with moderate-to-severe plaque psoriasis: results from a phase III international randomized, placebo-controlled trial. Br J Dermatol (2006) 1.10
Pneumoperitoneum with carbon dioxide stimulates growth of malignant colonic cells. Surgery (1997) 1.10
Influence of monomethylfumarate on monocytic cytokine formation--explanation for adverse and therapeutic effects in psoriasis? Arch Dermatol Res (1997) 1.09
Peripheral blood T cell clonality in mycosis fungoides -an independent prognostic marker? J Invest Dermatol (2000) 1.08
Contact urticaria and dermatitis from self-adhesive pads. Contact Dermatitis (1985) 1.08
Interferon gamma-1b in the treatment of compensatory anti-inflammatory response syndrome. A new approach: proof of principle. Arch Intern Med (1997) 1.06
Identification of gene markers for the prediction of allograft rejection or permanent acceptance. Am J Transplant (2007) 1.05
Characterization of ZK 245186, a novel, selective glucocorticoid receptor agonist for the topical treatment of inflammatory skin diseases. Br J Pharmacol (2009) 1.05
Flow cytometric characterization of lesional T cells in psoriasis: intracellular cytokine and surface antigen expression indicates an activated, memory/effector type 1 immunophenotype. Arch Dermatol Res (2000) 1.05
Case report. Osteomyelitis caused by high resistant Candida guilliermondii. Mycoses (1999) 1.04
Adhesion molecule mapping in normal human skin. Arch Dermatol Res (1989) 1.04
The use of Toll-like receptor-7 agonist in the treatment of basal cell carcinoma: an overview. Br J Dermatol (2003) 1.04
Distribution of bacteria in the epidermal layers and hair follicles of the human skin. Skin Pharmacol Physiol (2011) 1.03
TGF-beta1 mRNA upregulation influences chronic renal allograft dysfunction. Kidney Int (2006) 1.02
Online lectures for students in dermatology: a replacement for traditional teaching or a valuable addition? J Eur Acad Dermatol Venereol (2009) 1.01
A family study of atopic dermatitis. Clinical and genetic characteristics of 188 patients and 2,151 family members. Arch Dermatol Res (1990) 1.01
Very low monocytic HLA-DR expression indicates high risk of infection--immunomonitoring for patients after neurosurgery and patients during high dose steroid therapy. Eur J Emerg Med (1995) 1.00
Progression of mycosis fungoides is associated with increasing cutaneous expression of interleukin-10 mRNA. J Invest Dermatol (1996) 1.00
Induction of apoptosis by Toll-like receptor-7 agonist in tissue cultures. Br J Dermatol (2003) 0.99
Tumor suppressor TNFAIP3 (A20) is frequently deleted in Sézary syndrome. Leukemia (2011) 0.99
Reflectance confocal microscopy for noninvasive monitoring of therapy and detection of subclinical actinic keratoses. Dermatology (2009) 0.99
Mycetoma due to Exophiala jeanselmei and Mycobacterium chelonae in a 73-year-old man with idiopathic CD4+ T lymphocytopenia. Mycoses (1996) 0.99
Familial juvenile onset psoriasis is associated with the human leukocyte antigen (HLA) class I side of the extended haplotype Cw6-B57-DRB1*0701-DQA1*0201-DQB1*0303: a population- and family-based study. J Invest Dermatol (1996) 0.98
CD4+CD7- leukemic T cells from patients with Sézary syndrome are protected from galectin-1-triggered T cell death. Leukemia (2002) 0.98
Mapping protein-protein contact sites using cellulose-bound peptide scans. Mol Divers (1996) 0.97
Demonstration of frequent occurrence of clonal T cells in the peripheral blood of patients with primary cutaneous T-cell lymphoma. Blood (1997) 0.97
Heightened expression of the cytotoxicity receptor NKG2D correlates with acute and chronic nephropathy after kidney transplantation. Am J Transplant (2006) 0.96
Induction of pre-transplant Epstein-Barr virus (EBV) infection by donor blood transfusion in EBV-seronegative recipients may reduce risk of post-transplant lymphoproliferative disease in adolescent renal transplant patients: report of two cases. Transpl Infect Dis (2006) 0.96
Effects of GUG and AUG initiation codons on the expression of lacZ in Escherichia coli. FEBS Lett (1986) 0.95
Interleukin 10 treatment of psoriasis: clinical results of a phase 2 trial. Arch Dermatol (1999) 0.95
Hybrid cell vaccination for cancer immune therapy: first clinical trial with metastatic melanoma. Int J Cancer (2000) 0.95
Mapping of the interleukin-10/interleukin-10 receptor combining site. Protein Sci (1998) 0.95
In vivo methods for the analysis of the penetration of topically applied substances in and through the skin barrier. Int J Cosmet Sci (2012) 0.94
Exploring the association between cardiovascular and other disease-related risk factors in the psoriasis population: the need for increased understanding across the medical community. J Eur Acad Dermatol Venereol (2010) 0.94
Comparison of monocyte functions after LPS- or IL-10-induced reorientation: importance in clinical immunoparalysis. Pathobiology (1999) 0.93
Efficient tetanus toxoid immunization on vitamin D supplementation. Eur J Clin Nutr (2011) 0.93
Expression of the B7/BB1 activation antigen and its ligand CD28 in T-cell-mediated skin diseases. J Invest Dermatol (1994) 0.93
Provirus variants of the bovine leukemia virus and their relation to the serological status of naturally infected cattle. Virology (1997) 0.93
Association between interleukin-1 receptor antagonist (IL-1ra) gene polymorphism and early and late-onset psoriasis. Br J Dermatol (1997) 0.93
Common pathogenetic pathways in allergic and irritant contact dermatitis. J Invest Dermatol (1992) 0.93
Subclinical activation of latent cytomegalovirus (CMV) infection and anti-CMV immune response in patients with atopic dermatitis. Br J Dermatol (2003) 0.93
HDL is the major source of vitamin E for type II pneumocytes. Free Radic Biol Med (1999) 0.93
Monoclonal gammopathy of undetermined significance (MGUS) is associated with an increased frequency of Epstein-Barr Virus (EBV) latently infected B lymphocytes in long-term renal transplant patients. Transplant Proc (2004) 0.93
The pathogenetic mechanism of anthracycline-induced palmar-plantar erythrodysesthesia. Anticancer Res (2009) 0.93
Effects of local and systemic viral interleukin-10 gene transfer on corneal allograft survival. Gene Ther (2006) 0.92
Shedding of the soluble form of CD30 from the Hodgkin-analogous cell line L540 is strongly inhibited by a new CD30-specific antibody (Ki-4). Int J Cancer (1995) 0.92
Cloning of murine IL-22 receptor alpha 2 and comparison with its human counterpart. Genes Immun (2004) 0.92